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ABSTRACT 
Mammalian AMP-activated protein kinase (AMPK) is a serine/threonine protein 
kinase that acts as a sensor of cellular energy status. It is activated by a large variety of 
cellular stresses that increase cellular AMP and decrease ATP levels and also by 
physiological stimuli, such as muscle contraction, or by hormones such as leptin and 
adiponectin. AMPK modulates multiple metabolic pathways. As a result, it has become 
a target for the development of new drugs for the treatment of type II diabetes, obesity 
or even cancer. In fact, it has been recently reported that drugs used in the treatment of 
diabetes, such as metformin and thiazolidinediones (TZDs), exert their beneficial effects 
through the activation of AMPK. AMPK is a heterotrimeric complex composed of a 
catalytic subunit (AMPK-) and two regulatory subunits (AMPK- and AMPK-). 
Functional orthologues of this kinase complex are found throughout eukaryotic 
kingdom, from yeast to humans, indicating that the function of this complex is 
evolutionarily conserved. This review summarizes the recent studies on the structure 
and regulation of the AMPK heterotrimeric complex. 
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1.- INTRODUCTION 
Mammalian AMP-activated protein kinase (AMPK) is a serine/threonine protein 
kinase that acts as a sensor of cellular energy status. It is activated in an ultrasensitive 
manner by cellular stresses that deplete ATP (concomitant increase in AMP levels), 
either by inhibiting ATP production (hypoxia, glucose deprivation, heat shock, 
mitochondrial oxidative phosphorylation inhibitors, etc.) or by accelerating ATP 
consumption (muscle contraction, etc.). Once activated, it switches on catabolic 
pathways and switches off many ATP-consuming processes (anabolic pathways) (see 
[1], [2], [3], [4], [5], for reviews). AMPK is a heterotrimer of three different subunits: , 
 and . Phylogenetic analysis of the three subunits indicates that all of them have 
orthologues in the eukaryotic kingdom, from yeast to humans, thus indicating that the 
function of this complex is well conserved throughout evolution ([6], [7]). AMPK- is 
the catalytic subunit of the AMPK complex; it contains a highly conserved kinase 
domain (KD), including the catalytic site, located at the N-terminus of the protein, and a 
regulatory domain (RD) located at the C-terminus of the subunit [6]. Two isoforms of 
the catalytic subunit have been described, namely AMPK-1 and AMPK-2; both are 
localized in the cytoplasm, although AMPK-2 shows also a nuclear localization [8]. 
The AMPK-subunit contains four tandem repeats of a structure module called CBS, 
described initially in cystathionine--synthase [9], involved in AMP binding [10]. Three 
isoforms of the -subunit, named AMPK-1, 2 and 3, have been described; they differ 
at the N-terminal part of the proteins, whereas the C-terminus (where the CBS domains 
are located) is conserved in the three isoforms. AMPK- subunit functions as a scaffold 
to assemble  and  subunits, and also determines the subcellular localization and 
substrate specificity of the complex. Two isoforms of the -subunit (AMPK-1 and 2) 
have been described; they only differ at the N-terminus, but interact with the same 
efficiency with AMPK- and AMPK- subunits ([11], [12]). 
AMPK function has been implicated in multiple metabolic pathways. Several 
excellent reviews have recently appeared covering the involvement of AMPK in the 
function of different tissues, such as skeletal muscle [13], heart [14], liver [15], adipose 
tissue [16], hypothalamus [17], and in processes such as mitochondrial biogenesis [18] 
and cell proliferation [19]. To activate AMPK, two processes must occur: 
phosphorylation of the Thr172 residue in the catalytic domain and allosteric activation 
by AMP. The combination of these two effects causes a more than 1000 fold increase in 
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kinase activity [20]. In this review, I summarize the recent studies on the structure of the 
different AMPK subunits and also those involved in the regulation of the activity of the 
AMPK complex. 
 
2.- STRUCTURAL STUDIES ON AMPK- SUBUNIT 
As mentioned above, two isoforms of the catalytic subunit of AMPK have been 
described, namely AMPK-1 and AMPK-2. AMPK-1 is a protein of 548 aa (63 
kDa) encoded by the PRKAA1 gene; AMPK-2 is a protein of 552 aa (63 kDa) 
encoded by the PRKAA2 gene. Both subunits contain the kinase domain (KD) at the N-
terminus (residues 1-312), plus a C-terminal regulatory domain (RD) (residues 313-548, 
in 1; 313-552, in 2) involved in the interaction with the AMPK- and AMPK- 
subunits (see below). AMPK- has a well-defined orthologue in the yeast 
Saccharomyces cerevisiae named Snf1. It is a protein of 633 aa (72 kDa) that also 
contains an N-terminal kinase domain (residues 1-391) and a C-terminal regulatory 
region (residues 392-633) (Fig. 1A). 
The N-terminal kinase domain of the AMPK- family is conserved throughout 
evolution; for example, it is 47% identical (61% homology) to that of the yeast Snf1 or 
plant SnRK1 (Snf1 related kinase) [6]. However, the C-terminal regulatory domain is 
divergent. The kinase domain contains the Thr172 residue whose phosphorylation is 
critical for activity (see below). It is assumed that in the non-phosphorylated inactive 
form of AMPK-, the KD domain interacts with an auto-inhibitory region located in the 
RD domain (residues 313-392; AID) [6]. Interaction of AMPK- with the C-terminal 
domain of AMPK- counteracts the function of the auto-inhibitory domain (AID) ([21], 
[22]) (Fig. 1A). Recently, the residues involved in auto-inhibition have been studied in 
more detail. It was found that a conserved short segment of the -subunit (residues 313-
335 in 1) was responsible for the auto-inhibition. In this sequence, several 
hydrophobic and charged residues, in particular Leu-328, were found to be critical for 
1 auto-inhibition. It was also found that Leu328 interacted with Val298 in the kinase 
domain, and mutations such as L328Q or V298G that abolished the interaction, 
conferred a constitutive activity to a truncated from (residues 1-394) of the AMPK- 
subunit. However, deletion of the (313-335) domain in the full length AMPK-1 
subunit did not fully activate the kinase domain. Therefore, additional interactions 
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between the kinase domain (1-312) and the regulatory domain (313-548) may also be 
responsible for the auto-inhibition [23]. 
Due to this auto-inhibitory reaction, short forms of the  subunits containing 
only the kinase domain (i.e. residues 1-312) have been constructed and used as 
constitutively active forms of the enzyme. Although these truncated forms are initially 
inactive, they become active upon phosphorylation of Thr172 residue or by replacing 
this residue by an Asp or Glu (T172D/E), mimicking the negative charge of the 
phosphate [24]. Alternatively, a recent report describes the isolation of small molecules 
that activate AMPK through antagonizing the auto-inhibition of  subunits. One of 
these small activators, named PT1, interacts with Glu96 and Cys156 residues, which are 
structurally close to the auto-inhibitory domain of AMPK-1, and directly relieves 
auto-inhibition. PT1 enhances also AMPK phosphorylation at Thr172 without 
increasing the AMP/ATP ratio [25]. 
 
 Several attempts were made initially to define the crystal structure of AMPK- 
subunit. Two reports partially defined the crystal structure of the kinase domain of the 
yeast AMPK- orthologue, Snf1. In the first report, the kinase domain of Snf1 (residues 
41-315) (Snf1-KD) was crystallized and its structure determined by single-wavelength 
anomalous dispersion of selenomethionyl protein derivatives (PDB, 2EUE) (Fig. 2A). 
The structure shared strong similarity to other protein kinases (PKA, CaMK, etc), with a 
small N-terminal lobe (with five -sheets and a -helix) and a large C-terminal lobe 
mostly helical (6 -helices). Two negative surface patches in the structure were defined 
as important for the recognition of the substrates by this kinase, and the regulatory 
Thr210 residue presumably located on the top of the cleft between the N-terminal and 
the C-terminal lobes (unfortunately, the structure is disordered in this area so the precise 
location of the Thr210 residue could not assigned) [26]. Other authors crystallized a 
similar kinase domain of Snf1 (residues 33-320) (PDB, 2FH9) (Fig. 2B). They found a 
similar bilobe fold and defined the ATP binding residues in a grove formed between the 
two lobes. However, and in contradiction with the previous crystal structure studies, 
these authors indicated that the kinase domain was able to form dimers, that they 
confirmed experimentally by gel-filtration and equilibrium centrifugation. The 
introduction of an I257E mutation, in the dimerization domain, prevented dimer 
formation. The authors also indicated that full-length Snf1 was able to form dimers and 
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suggested that the dimer conformation was inactive, since the catalytic site would be 
buried by the second protomer. It was proposed then that disruption of the dimer was 
necessary to gain full activation of the Snf1 kinase complex [27]. 
Recently the kinase domain of AMPK-2 (residues 4-279) was crystallized 
(PDB, 2H6D) (Fig. 2C). Apparently, it displays a similar monomeric structure to Snf1 
KD (residues 41-315) (unpublished results from the Structural Genomics Consortium). 
 
3.- STRUCTURAL STUDIES ON AMPK- SUBUNIT 
Two isoforms of the AMPK- regulatory subunit have been described, namely 
AMPK-1 and AMPK-2. AMPK-1 is a protein of 270 aa (38 kDa) encoded by the 
PRKAB1 gene, and AMPK-2 is a protein of 271 aa (34 kDa) encoded by the PRKAB2 
gene (Fig. 1B). They are 71% identical and differ only at the N-terminus [11]. AMPK-
subunits function as a scaffold to assemble  and  subunits, via binding to their 
conserved KIS (kinase interacting sequence) and ASC (association with Snf1 complex) 
domains, respectively. The KIS and ASC domains are also present in yeast -subunits 
[Gal 83 (Fig. 1B); Sip1 and Sip2], although these proteins show a divergent N-terminal 
domain. Recently, a new domain in the -subunits has been defined: it is the glycogen 
binding domain, GBD, which extends from residues 68 to 163 inside the formerly 
defined KIS domain. GBD binds glycogen and can lead to abnormal glycogen-
containing inclusions when the heterotrimeric complex is overexpressed. These 
inclusions are absent when GBD-truncated forms of  subunits or  subunits mutated in 
residues involved in glycogen binding (W100G, K126Q) are used ([28], [29]). The 
truncated  subunits lacking the entire GBD domain still form regular complexes with  
and  subunits, which are fully active and regulated normally, indicating that that GBD 
domain is not critical for activity. On the contrary, the ASC domain is essential for 
activity. Deletion of small parts of this domain leads to forms that can no longer 
assemble in complexes and are inactive, indicating that the ASC domain is required for 
the formation of a stable, active  complex ([28], [29]). 
AMPK- subunits are phosphorylated at multiple sites, Ser24/25, Ser108 and 
Ser182 (AMPK-2 lacks Ser24/25 site). Ser24/25 and Ser108 are autophosphorylated 
by AMPK-1, whereas Ser182 is phosphorylated by an upstream AMPK kinase. 
Although none of the mutations in the phosphorylation sites of AMPK-1 subunit affect 
the rate of phosphorylation of AMPK-1 at Thr172, phosphorylation of Ser24/25 and 
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Ser182 residues is necessary for the nuclear exclusion of 1 subunit, and 
phosphorylation of Ser108, although it does not affect subcellular distribution of 
AMPK-, increases AMPK activity [30]. 
In addition, -subunits are myristoylated at the N-terminus on Gly2 [31]. The 
elimination of the myristoylation site results in a more homogeneous distribution of the 
AMPK- subunits inside the cell and in an increase in AMPK activity [30]. 
 
The crystal structure of AMPK--GBD (residues 68-163) complexed with -
cyclodextrin has been determined (PDB, 1Z0M) (Fig. 3A). This GBD is remarkably 
similar to the major carbohydrate binding site of the starch binding domains in 
cyclodextrin glycosyltransferase, -amylase and glucoamylase. This study defined the 
residues involved in the interaction with the carhohydrate, which were W100, K126, 
W133, L146 and N150. Five sugars can be accommodated in the structure of the GBD, 
suggesting that malto-pentaose is the smallest oligosaccharide that could prevent 
glycogen from binding to AMPK [32]. The Structural Genomics Consortium has also 
deposited the structure of AMPK-2-GBD (residues 68-163) without -cyclodextrin 
(PDB, 2F15). Apparently, this structure is similar to the one from 1-GBD. 
 
4.- STRUCTURAL STUDIES ON AMPK- SUBUNIT 
Three different AMPK- subunits have been described. AMPK-1 is a protein of 
331 aa (37 kDa), AMPK-2 is a protein of 569 aa (63 kDa) and AMPK-3 is a protein 
of 492 aa (55 kDa), encoded by the PRKAG1, PRKAG2 and PRKAG3 genes, 
respectively. They differ at the N-terminal domain of the proteins, whereas the C-
terminal is conserved in the three isoforms (Fig. 1C). They bind 8-azido-AMP, as an 
indication of AMP binding [33]. The -subunits contain four tandem repeats of a 
structure module called CBS (cystathionine--synthase) [9], involved in AMP binding. 
The yeast orthologue Snf4 (322 aa; 36 kDa) also contains four CBS domains in the 
structure (Fig. 1C). The importance of these regions is highlighted by the presence of 
disease-causing mutations in the CBS domains of several CBS-containing proteins 
including AMPK, cystathionine -synthase, IMP dehidrogenase-1 and chloride channels 
CLC1 [10]. CBS domains occur in tandem pairs, refereed as Bateman domains (Fig. 
1C), and build the corresponding allosteric nucleotide binding site (AMP, ATP or SAM, 
depending of the CBS-containing protein). Biochemical studies indicate that in AMPK-
 8
, CBS1-CBS2 and CBS3-CBS4 each bind one AMP molecule with high affinity, while 
the binding of the second AMP molecule is cooperative. The AMP binding affinity is 
higher in complexes with 1 and lower in complexes with 3. CBS domains also bind 
ATP, but with lower affinity. However, higher levels of ATP can displace AMP from 
binding [10]. 
Recently, a conserved region of 20-25 amino acids immediately N-terminal to 
the first CBS domain (Pre-CBS) has been involved in the interaction with the  subunits 
and the formation of a functional active  complex (Fig. 1C). In addition, sequential 
truncations from the C-terminus of the  subunits indicate that deletion of any of the 
CBS domains prevents the formation of a functional complex with the  and  subunits 
[34]. 
-subunits are acetylated at the N-terminus. No other additional post-
translational modification has been described to date [31]. 
 
Recently, the crystal structure of a CBS domain pair from human AMPK-1 
(residues 182-325, comprising CBS3 plus CBS4) in complex with AMP and the 
pharmacological activator ZMP has been described (PDBs 2UV4 and 2UV5, 
respectively) [35]. The core of a CBS domain consists of a  structure in which 
the three -strands form a sheet with the two -helices to one side (Fig. 3B). This 
structure is homologous to those of other CBS-domain pairs already described ([36], 
[37]). A nucleotide-binding site sits between adjacent CBS domains and is formed from 
strands 1 and 7 of CBS4 and 2 and 3 of CBS3. AMP binds in a pocket lined by the 
side chains of residues Thr200, Ile204, Val225 and Ile312, making hydrogen bonds with 
surrounding residues [35]. Similar results were derive from the crystal structure of the 
second Bateman domain of the yeast AMPK- orthologue, Snf4 (residues 179-322, 
CBS3 plus CBS4; PDB, 2NYC) [38]. 
 
5.- STRUCTURAL STUDIES ON THE HETEROTRIMERIC COMPLEX 
In mammalian cells, co-expression of the three subunits is required for kinase 
activity. In the absence of one of the subunits, the other two are degraded, so extracts do 
not show significant levels of the expressed proteins. Therefore, the ternary complex 
stabilizes the kinase ([24], [39], [40]). Pull-down experiments have demonstrated the 
ternary nature of the complex: AMPK-1 and AMPK-2 associate with  and  
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subunits with similar intensity [39], and AMPK- interacts with both AMPK- and 
AMPK- subunits [41]. However, interaction between AMPK- and AMPK-subunits 
is prevented in the absence of AMPK- subunits ([42], [43]). 
Truncation experiments of AMPK- subunit indicate that the C-terminal 313-
552 domain is involved in binding to  and 1 ([12], [44]). Further studies shortened 
the sequence of AMPK-1 responsible for binding to 1 to residues 313-473 [42] (Fig. 
1A). In addition, it has been recently described that the N-terminal kinase domain of the 
2-subunit also participates in the binding to the 1-subunit [44].  
Several dominant negative forms of AMPK- have been constructed, i.e. K45R, 
D157N and T172A. In these cases, the substitution of critical residues located near or in 
the catalytic site completely abolishes the kinase activity of the enzyme (Fig. 2C). 
However, these forms are still able to bind to the AMPK- and AMPK- subunits and 
their overexpression results in a titration of the  and subunits from endogenous 
complexes, leading to the inhibition of AMPK activity ([31], [40], [45]). Similar results 
were obtained with an N-terminal truncated form of AMPK-1 containing residues 262-
548 [39]. 
The AMPK- subunit acts as a scaffold for  and  binding [42]. In the AMPK-
1 subunit, the C-terminal 85 residues (residues 186-270; ASC domain, Fig. 1B) are 
sufficient to interact with the three  and the two  subunits, and to form an active 
heterotrimer. The C-terminal 25 residues of 1 subunit (residues 246-270) still bind all 
three  subunits but not the  subunits and deletion of only the C-terminal Ile270 
precludes  association in the absence of  subunit [42]. In addition, a recent report 
indicates that the C-terminal region of 1 subunit (residues 186-270) can form a 
complex with 1 subunit in the absence of detectable  subunits [46]. The fact that only 
the C-terminal part of the -subunit is involved in binding to the other AMPK subunits 
was confirmed in plants, where it has been found that a new -subunit isoform 
(AKIN3), that lacks the N-terminal domain and also the GBD domain, is still able to 
interact with  and  subunits and form an active hetrotrimeric complex [47]. These 
results also confirmed that the GBD domain is not required for activity (see above). 
Recently, and in contrast to previous reports, it was described that the -subunits did not 
bind directly to the -subunits [44]; these authors suggested that the C-terminus of -
subunit binds to the C-terminus of the 2-subunit, which in turn binds to the -subunit, 
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but there is no direct interaction between the  and the subunits [44]. However, 
recent data on the crystal structure of the heterotrimeric complex (see below) does not 
support this later finding.  
 
The use of AMPK complexes synthesized in bacteria has allowed the 
identification of different phosphorylation sites within  and  subunits. Using a 
complex containing an AMPK-1 D157A mutation (that abolishes activity), it was 
found that an AMPKK preparation from liver phosphorylated the 1 subunit, but not 
the 1 or the 1. However, when using wild type or 1T172E (constitutively active), 
phosphorylation at the 1 subunit, in addition to 1 subunit, was observed. This results 
indicated: i) 1 contains alternative residues to Thr172 that are phosphorylated by 
AMPKK, and ii) 1 phosphorylation is due mainly to autophosphorylation by the 1 
subunit. By mass spectrometry analysis the residues that were phosphorylated by 
AMPKK in 1 were, Thr172, Thr258 and Ser485 (Ser491 in 2). Mutants were 
constructed altering these residues, but it was found that either T258D and S485D, or 
T285A and S485A in 1 did not affect overall AMPK activity [48]. However, recent 
results indicate that phosphorylation of Ser4851/4912 site by Akt/PKB or cAMP-
PKA prevents LKB1 (a major AMPKK; see below) phosphorylation at SerT172, 
decreasing the activity of AMPK ([49], [50], [51]). 
Mass spectrometry analysis also indicated that the residues phosphorylated in 
1, were Ser96, Ser101 and Ser108 [48]. These results are in contrast to previous 
reports that indicated that Ser24/25, Ser108 and Ser182 were the major phosphorylation 
sites in 1 [30]. 
 
All the biochemical and genetic data on the architecture of the heterotrimeric 
complex have been confirmed by the release in the year 2007 of three reports on the 
crystal structure of the complex from both yeast and mammalian cells, although in all 
the cases the kinase domain and the auto-inhibitory region of the  subunit and the N-
terminal domain of the  subunit are lacking (Table I). The first released structure 
corresponded to a complex composed by truncated forms of  and  subunits (residues 
440-576 and 205-298) and the entire  subunit (residues 1-334) from the yeast 
Schizosaccharomyces pombe (PDB, 2OOX) [52]. The second report corresponded to a 
complex composed by truncated forms of  and  subunits (residues 1 396-548 and 2 
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187-272) and the entire 1 subunit (residues 1-331) from mammalian (rat) AMPK 
(PDB, 2V8Q) [53], and the third, corresponded to the heterotrimeric core of the yeast 
Saccharomyces cerevisiae SNF1 complex composed by a truncated form of  subunit 
(but with a larger C-terminal regulatory domain; residues 398-633 of Snf1), a truncated 
form of  subunit (but containing the GBD domain; residues 154-415 of Sip2) and the 
entire  subunit (Snf4; residues 1-322), (PDB, 2QLV) [54]. The structures of the three 
core  complexes are very similar (Fig. 4A). They are triangular with a base formed 
by the  subunit which associates with a tight  complex (the C-terminal region of the 
 subunit forms a compact domain with the C-terminal region of the  subunit) that 
forms the apical domain. Structures show a direct  interaction mediated almost 
exclusively by hydrogen bonds and salt bridge interactions between three -strands, two 
provided by the C-terminus of the  subunit and one corresponding to the N-terminal 
region of the  subunit. The subunit forms an elliptical disk with an aqueous pore in 
the center. CBS domains 1 and 2 (first Bateman domain) form the interface with the  
complex and are connected to CBS domains 3 and 4 (second Bateman domain) that lay 
underneath. However, there are also differences among the three structures. First, there 
is a significant difference in the positions of the  and  subunits relative to the  
subunit, corresponding to a rotation of about 12º in their relative orientations, of the 
yeast S. pombe structure in comparison to the mammalian and the yeast S. cerevisiae 
ones. Second, in the case of the S. pombe and S. cerevisiae structures, they contained 
dimers of trimers ([52], [54]), whereas the mammalian structure was monomeric [53]. 
As described above, pairs of CBS domains participate in the binding of AMP. 
Since CBS1 and 2 form the first Bateman domain and CBS3 and 4 form the second 
Bateman domain, it could be expected that a  subunit could bind two molecules of 
AMP. However, since the two CBS motifs of the first Bateman domain also associate 
together in a pseudosymmetrical manner with the two CBS motifs of the second 
Bateman domain, two additional potential nucleotide-binding sites could be generated, 
making a total of four nucleotide-binding sites in each  subunit. All four sites are 
located between pairs of adjacent helix-loop-strands with an Asp residue from the 
corresponding -helix positioned to bind the nucleotide ribose hydroxyl residues, 
except for the site between CBS1 and CBS2, where an Arg is found instead of an Asp 
residue in the corresponding CBS2 chain. However, in the S. pombe structure only one 
adenine nucleotide is found, bound at the interface between CBS domains 3 and 4, 
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being the first Bateman domain (CBS1+2) unoccupied [52]. In the case of the S. 
cerevisiae structure, no nucleotide was initially found, although low-resolution data on a 
second crystal suggested the presence of one AMP in the same position (interface of 
CBS3+4) as in S. pombe [54]. In the case of the mammalian structure, three AMP are 
found [53]; one AMP is tightly bound and non-exchangeable in the interface of CB3+4, 
as in the yeast structures (AMP3 in Fig. 4B). However, two additional AMPs are 
located in the interfaces of CBS1+2 and CBS3+4 (AMP1 and AMP2 in Fig. 4B). These 
AMPs are interchangeable by ATP and are responsible for the adenyl-sensing properties 
of the mammalian enzyme. One site formed by the interface of CBS1+2 is unoccupied 
in the mammalian structure (AMP4 in Fig. 4B), maybe because of the absence of a 
conserved Asp residue in CBS2 positioned to bind the nucleotide ribose ring. Since the 
yeast structures do not contain AMP in sites corresponding to AMP1 and AMP2 (Fig. 
4B), this could be the reason why these enzymes do not respond to AMP. Recently, a 
new structure of S. pombe AMPK heterotrimer complexed with ADP has been 
described. In this case, two ADPs are found, one occupying the original AMP site 
(AMP3 in Fig. 4B) and the other in the unoccupied interface of CBS1+2 (AMP4 in Fig. 
4B) [55]. The significance of this finding is unclear, since no biochemical studies have 
been done on the S. pombe AMPK complex and no information is available on whether 
ADP could affect enzyme activity. 
Since the structure of the S. cerevisiae SNF1 complex contains larger fragments 
of the  (Snf1) and  (Sip2) subunits, it defines new structural features not present in 
the other structures. First, the GBD domain of the  subunit (residues 154-247 of Sip2) 
has close interactions with the rest of the heterotrimer, primarily with the N-terminal 
region and an -helix of CBS2 of Snf4 (Fig. 4A). The putative binding site for 
carbohydrates is exposed to the solvent and should be available for binding ligands in 
this complex. This feature is interesting although, in the case of the mammalian  
subunit, the GBD plays no role in the regulation of AMPK activity (see above). Second, 
residues 460-495 of Snf1 ( subunit), corresponding to the regulatory region (RD), have 
well defined interactions with Snf4 ( subunit) (residues 467-469 of Snf1 interact with 
residues 270-275 of the first -strand of CBS4 of Snf4) (Fig. 4A). This demonstrates a 
direct interaction between the  and the  subunits in SNF1 complex, which is fully 
supported by earlier biochemical and genetic data [54]. The authors suggested that the 
structure having the RD sequence bound to  subunit should correspond to the active 
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conformation of the SNF1 complex. It remains to be determined how the binding of 
different ligands to the  subunit can control its interaction with the RD sequence and 
how this RD sequence is recognized by the protein kinase domain in the inactive 
conformation of the complex. In spite of this, the interaction between the RD sequence 
and the  subunit is particularly interesting since a disease-causing mutation in the 
mammalian 2 subunit (see below), namely N488I (equivalent to Asn251 on Snf4), 
maps in the same region and could be affecting the binding of the 2 subunit to the C-
terminal regulatory domain of  subunit, explaining in this way the absence of 
regulation of the mutated 2 subunit [54]. 
Mutations in the  subunit have been associated with disease. Up to ten different 
point mutations in the mammalian 2 subunit cause heart disease characterized by 
excessive glycogen storage in cardiac myocytes, what leads to ventricular pre-excitation 
[56]. All these mutations reduce binding and activation by AMP [10]. Since the 
structure of the  subunit is now available, it has been possible to map the position of 
the residues involved in pathogenesis. In this way, it has become clear that nine out of 
the ten mutations that have been characterized involve amino acids lining the interior 
surface of an internal cavity formed in each Bateman domain and, in the case of 
2Arg302, 2His383, 2Arg384, 2Thr400, 2Arg531, their side chains are in the 
proximity to the adenyl-binding sites. 
When comparing the structures of the heterotrimers obtained in the presence of 
AMP or ATP, no major difference is observed in terms of movement of the 
corresponding CBS domains. This was quite unexpected since it was anticipated to see 
a change in the conformation of the CBS domains depending on which nucleotide was 
bound. Perhaps the absence of critical domains in the crystallized core structures, such 
as the catalytic and autoinhibitory regions of  subunit, could account for this 
unexpected result. This leaves open the question of how the binding of AMP activates 
the AMPK complex. However, very recently, an answer to this question has been 
provided [57]. These authors purified large quantities of mammalian heterotrimeric 
complexes containing, this time, full length untagged ,  and  subunits from 
mammalian AMPK and described the biophysical characterization of the heterotrimers 
by small angle X-ray scattering in solution, transmission and scanning transmission 
electron microscopy and mass spectrometry. All these techniques revealed that 
mammalian AMPK heterotrimers were elongated flat particles with protrusions and 
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indentations. More importantly, addition of AMP resulted in a significant change in the 
conformation of the heterotrimer towards a more compact structure. The change in the 
conformation of the  subunit upon AMP binding could be transmitted via the 
regulatory domain (RD) of the  subunit onto the kinase domain: the RD could be 
relocated, releasing in this way the kinase domain from its auto-inhibition. These 
changes may also alter the accessibility of the phospho-Thr172 residue, thus positively 
affecting AMPK activity [57]. 
 
6.- RELATIONSHIP BETWEEN MAMMALIAN AMPK AND YEAST SNF1 
COMPLEXES. 
Due to the considerable similarity between the mammalian AMPK and the yeast 
SNF1 complex, the yeast system has been used to investigate AMPK regulation. 
Attempts have been made to complement SNF1 subunit deficiencies with their 
mammalian counterparts, however full recovery of the corresponding snf1 phenotype 
has never been achieved. In this way, expression of AMPK-1 or 2 in yeast does not 
complement snf1 mutants [41], expression of AMPK-1, 2 or 3 does not complement 
snf4 mutants [41] and expression of AMPK-1/2 does not complement sip1 sip2 gal83 
mutants (personal observation). These results were quite surprising since AMPK- 
interacts with Snf1 and Snf4, AMPK- interacts with Snf1 and Gal83 and AMPK- 
interacts with Gal83 although it does not interact with Snf4 (personal observation). 
Chimeras containing the N-terminus of AMPK-1 (residues 2-261) and the C-
terminus of Snf1 (residues 300-633) (1-Snf1), and also the opposite, N-terminus from 
Snf1 (residues 2-299) and C-terminus from AMPK-1 (residues 262-548) (Snf1-1) 
have been constructed. Two-hybrid analysis revealed that the 1-Snf1 chimera 
associated with Sip2 and Snf4, but not with the mammalian counterparts, and that the 
Snf1-1 chimera associated with mammalian 1 and 1 subunits, but not with the yeast 
counterparts [58]. This indicates that the C-terminal part of the  subunit defines a cell-
specific interaction profile with the corresponding  and  subunits. This is in agreement 
with the fact that -subunits are more divergent at their C-terminus (see above). The 
chimeras were expressed in mammalian cells and it was found that, as in the case of 
regular AMPK-1, the expression of Snf1-1 chimera was dependent on the co-
expression of AMPK-1 and AMPK-1 subunits, whereas the expression of 1-Snf1 
chimera in mammalian cells was dependent on the co-expression of yeast Sip2 and 
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Snf4. The Snf1-1 chimera produced inactive heterotrimeric complexes. However, the 
1-Snf1 chimera showed significant kinase activity that was unaffected by AMP. Since 
the SNF1 complex is not allosterically activated by AMP [59], it was concluded that the 
C-terminal domain of AMPK-1 (absent in the chimera) was involved in AMP 
regulation [58]. This 1-Snf1 chimera was able to form a functional kinase complex 
when expressed in yeast, via association with the endogenous regulatory subunits, and 
was also able to display significant kinase activity under low-glucose conditions [58]. 
 
7.- REGULATION OF AMPK ACTIVITY 
7.1.- AMPK activation. 
The AMP-activated protein kinase is a sensor of cellular energy charge. This 
system is activated in an ultrasensitive manner by cellular stresses that increase the 
AMP/ATP ratio. AMP activates mammalian AMPK by two mechanisms: i) allosteric 
activation of AMPK, and ii) binding to AMPK making it a worse substrate for 
phosphatases. This allows a >200 fold activation of AMPK. All these effects are 
reversed by ATP, indicating that AMPK has a single allosteric site that binds both AMP 
and ATP in a mutually exclusive manner ([6], [20], [60], [61], [62]). 
Activation of AMPK correlates with phosphorylation at the Thr172 within the 
“activation loop” of the kinase domain ([63], [64]). This phosphorylation is achieved by 
an upstream AMPK kinase (AMPKK; see below). Phosphorylation of Thr172 is 
necessary and sufficient for AMPK activity, since a T172A mutant shows no enzymatic 
activity, whereas a T172D mutant possesses detectable activity (40-50% of regular 
activity) which is not affected by phosphatase treatment [65]. The modification of the 
Thr172 does not affect interaction with the  and subunits. For this reason the T172A 
mutant can be used as a dominant negative form of the AMPK- subunit [31]. These 
results are in contrast with the ones obtained in the yeast orthologue Snf1 (-subunit), 
where it has been found that, although a change in the corresponding Thr172 (T210A) 
eliminates SNF1 activity, the mutated form is unable to interact with Snf4 (-subunit) 
[21]. 
In yeast, regulation of the activity of the Snf1 complex  involves two steps, one 
that requires phosphorylation of the Snf1 catalytic subunit (-subunit) by an upstream 
protein kinase and another that is mediated by the interaction between Snf4 (-subunit) 
and Snf1 (-subunit) [21]. Phosphorylation of Thr210 can occur independently of the 
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Snf4 step, but to achieve full activity, the complex has to undergo a Snf4-dependent 
rearrangement [66]. Interaction with Snf4 is required for efficient activation because it 
counteracts the function of an auto-inhibitory domain present in the C-terminus of the 
-subunit ([21], [22]). After these two steps, the phosphorylated Snf1 kinase (Thr210-P) 
opens its active site, making it accessible to substrates (Fig. 5A). Regulation of AMPK 
activity follows a similar trend, including phosphorylation of a conserved Thr172 
residue of AMPK- by an upstream kinase and AMPK- dependent allosteric regulation 
by AMP. The identification of the putative AMPK upstream protein kinase was a 
frustrating project until the discovery of yeast Snf1 upstream kinases: Sak1, Elm1 and 
Tos3 ([67], [68], [69]). They are monomeric protein kinases, being Sak1 the most 
important upstream kinase in the glucose repression pathway and the only one that 
forms a stable complex with Snf1 ([70], [71], [72]). Sak1, Elm1 and Tos3 are members 
of the ELM family of protein kinases [73]. While none of them had a clear mammalian 
homologue, their kinase domains were most closely related to those of the protein 
kinase LKB1, and the calmodulin-dependent protein kinase kinases CaMKK and 
CaMKK. Evidence came rapidly indicating that all three, but especially LKB1 and 
CaMKK phosphorylated AMPK- at Thr172 and thus activated AMPK in vivo ([74], 
[75], [76], [77]). The relationship between the upstream kinases in yeast and mammals 
was reinforced when it was described that the expression in yeast of mammalian LKB1 
and CaMKK phosphorylated and activated Snf1 at its corresponding Thr210 site [78]. 
Recently, a genetic selection for mammalian Snf1-activating kinases in yeast identified 
TAK1 (transforming growth factor--activated kinase), a member of the mitogen-
activated protein kinase kinase kinase family (MAPKKK), as an additional AMPK 
upstream kinase [79] (Fig. 5B). 
 
7.1.1.- AMPKK: LKB1 
LKB1 is a tumor suppressor kinase related to the Peutz-Jeghers cancer syndrome 
[80]. As mentioned above, it is an upstream AMPK kinase (AMPKK), since it can 
phosphorylate in vitro AMPK [68], and it accounts for most of the AMPKK activity 
detectable in cell extracts [1]. LKB1 is found in complexes with STRAD/ (Ste20 
Related Adaptor; an inactive pseudokinase) [81] and MO25/mouse protein 25an 
armadillo-repeat scaffolding-like protein) [82]. The ternary complex is required for 
activity since in the absence of STRAD or MO25, no activity is observed. The crystal 
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structure of MO25 in complex with the C-terminus of STRAD has been recently 
described and indicates that MO25 acts as a scaffold protein for binding of 
STRAD/LKB1, LKB1 substrates or other regulatory components of the system [83]. 
Structurally, the kinase domain of LKB1 binds to the pseudokinase domain of STRAD, 
and MO25 binds to the C-terminal residues of STRAD, stabilizing the binding of 
STRAD to LKB1 ([81], [82]). Mutations in LKB1 isolated in Peutz-Jeghers patients fail 
to interact with STRAD-MO25, thus defining one of the reasons for this pathology [84]. 
LKB1 is truly an AMPK kinase since immunoprecipitation with anti-LKB1 antibodies 
reduces AMPK activity and recombinant complexes of LKB1-STRAD-MO25 activate 
AMPK via phosphorylation of AMPK- at Thr172 in the activation loop. It has also 
been found that chemical activators of AMPK activity such as AICAR and phenformin 
(see below) do not activate AMPK in cells lacking LKB1 (i.e. HeLa cells), but 
activation can be restored by stably expressing LKB1 in these cells. The same results 
were obtained with fibroblasts from LKB1 knock-out mouse embryos: neither AMP nor 
phenformin directly stimulated the AMPK complex. All these results suggest that 
LKB1-STRAD-MO25 is a major upstream regulator of AMPK ([74], [75], [85], [86]). 
LKB1 is the major upstream activating kinase for AMPK in skeletal muscle. 
Using mice in which expression of LKB1 has been reduced to only 10% in skeletal 
muscle or completely abolished (LKB1 skeletal muscle conditional knock-out), it was 
observed that LKB1 was required for AICAR-induced activation of AMPK2. LKB1 
was also required for contraction-induced AMPK activation and also for contraction-
induced glucose transport in skeletal muscle. These results indicate that contraction-
induced glucose uptake operates via an LKB1 dependent pathway, that could activate 
AMPK or some other AMPK related kinases to improve glucose uptake [87]. 
LKB1 is also the major upstream activating kinase for AMPK in liver. Liver 
specific deletion of LKB1 reduces substantially AMPK phosphorylation and activity, 
which leads to a marked hyperglycemia due to an increased hepatic gluconeogenic and 
lipogenic gene expression. However, peripheral glucose uptake (skeletal muscle) was 
not affected. LKB1 deletion increased expression of gluconeogenic genes (such as 
PEPCK and G6Pase) due to an increase in expression of peroxisome proliferator-
activated receptor- co-activator 1 (PGC-1), whose expression was improved by a 
better activity of the CREB transcription factor. It has been recently described that the 
activity of CREB is regulated positively by TORC2 (transducer of regulated CREB 
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activity 2) and that AMPK and other related kinases phosphorylate TORC2 promoting 
its inactivation and sequestration by 14-3-3 proteins in the cytoplasm. As a result of 
LKB1 deficiency, lower AMPK activity leads to more unphosphorylated TORC2 that 
may activate CREB, which in turn activates PGC-1, thus activating the expression of 
gluconeogenic genes. Lipogenesis was also improved in LKB1 knock-out animals, 
since lower AMPK activity leads to the improved expression of sterol regulatory 
element binding protein 1 (SREBP1), which improved the expression of target genes 
(FAS, ACC1, L-PK) [88], as AMPK is a negative regulator of SREBP1 [89]. 
 
7.1.2.- Alternatives to LKB1: CaMKK 
LKB1 is related to activation of AMPK caused by a change in the AMP/ATP 
ratio. However, there are examples were AMPK is activated without changes in this 
ratio: a) During mild ischemia the ratios AMP:ATP and creatin/creatin-P are not altered, 
but AMPK activity and AMPKK activities are increased [90]; b) In several cell lines 
that do not express LKB1 (i.e. HeLa cells), AMPK is activated and phosphorylated in 
response to growth factors, such as Insulin growth factor 1 (IGF-1), by a LKB1-
independent pathway [91]. 
The characterization of additional upstream kinases for activating AMPK came 
from the observation that the AMPKK activity present in LKB1-deficient cells was 
stimulated by Ca++ ionophores and inhibited by STO-609, a specific inhibitor of 
CaMKK, and by specific siRNAs corresponding to CaMKK. It was then defined that 
CaMKK was an additional upstream AMPK kinase, that also phosphorylated AMPK-
 at residue Thr172. It is worth pointing out that CaMKKs are significantly expressed in 
neurons, where activation of AMPK may be a mechanism for anticipating the increased 
demand for ATP that always accompanies rises in cytosolic Ca++ [4]. In fact, K+ 
induced depolarization in rat cerebrocortical slices, which increases intracellular Ca++ 
without disturbing cellular adenine nucleotide levels, activates AMPK and this is 
prevented by STO-609. Therefore, there is a potential Ca++-dependent neuroprotective 
pathway involving phosphorylation and activation of AMPK by CaMKK ([76], [77], 
[92]). 
These results indicate the existence of two converging pathways of AMPK 
regulation: one directed by LKB1, which is affected by changes in AMP levels, and 
another directed by CaMKKs, dependent on changes in intracellular Ca++. Since AMPK 
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(AMP-activated protein kinase) is additionally activated by Ca++, some authors have 
suggested a new name for this protein: PKE, for protein kinase energy or economy 
kinase [93]. 
 
7.1.3.- Alternatives to LKB1: TAK1. 
As described above, a genetic selection for mammalian Snf1-activating kinases 
in yeast identified TAK1 (transforming growth factor--activated kinase) as an 
additional AMPK upstream kinase [79]. TAK1 is able to phosphorylate AMPK- at 
Thr172, and expression of TAK1 and its binding partner TAB1 in HeLa cells (that lack 
LKB1) or treatment of these cells with cytokines (which stimulates the TAK1 signalling 
pathway) stimulated phosphorylation of Thr172 in AMPK-[79]. However, more work 
needs to be done to determine the importance of this upstream kinase in cellular 
physiology. 
 
7.2.- Methods for activating AMPK. 
 In yeast, the activity of the Snf1 kinase is regulated by glucose: in low glucose 
growing cells, the Snf1 kinase is active (phosphorylated), whereas in high glucose 
containing media, the Snf1 kinase is inactive (dephosphorylated) [21]. Signalling 
requires uptake and phosphorylation of the sugar, but unlike mammalian AMPK, Snf1 
is not activated directly by AMP [59]. Similarly, mammalian AMPK can be activated 
by subjecting the cells to different stress conditions or by treating them with different 
activating compounds. The activating conditions of AMPK can be classified in two 
groups, those that increase the AMP/ATP ratio, and hence activate AMPK via LKB1, 
and those where the activation of AMPK is independent of the AMP/ATP ratio, where 
alternative AMPKK are involved [62] (Table II): 
 
7.2.1.- AMPK activating compounds that increase AMP/ATP ratio. 
 AICA-riboside, 5-aminoimidazole-4-carboxamide-riboside (0.5-2.5mM). It is 
an activator of AMPK because it mimics the effects of AMP. It is cell permeable and 
produces ZMP after phosphorylation, an AMP analogue and an activator of AMPK. 
Activation occurs after 30 to 60 min and correlates with phosphorylation of Thr172 in 
AMPK- [94]. Although an important tool, AICAR’s utility is limited because: i) a 
triply phosphorylated form (ZTP) may also accumulate and act as an ATP analogue, 
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thus inhibiting AMPK in the long term; ii) ZMP mimics the effects of AMP on other 
AMP-sensitive enzymes, such as glycogen phosphorylase and fructose-1,6-
bisphosphatase; iii) AICAR may also act via adenosine receptors, adenosine 
transporters or both [95]. In this way, AICAR can lead to the AMPK-independent 
activation of glycogen phosphorylase, by an allosteric mechanism not shared by 
metformin [96]. AICAR can also compete with adenosine for uptake by the nucleoside 
transporter, resulting in an increase in extracellular adenosine and subsequent activation 
of adenosine receptors, by AMPK-independent mechanisms [97]. Additional AMPK-
independent effects of AICAR have been described recently ([98], [99], [100], [101], 
[102]). Therefore, when using AICAR, alternative activating AMPK conditions should 
always be used to make sure that the observed effect is dependent on AMPK activity. 
 Dinitrophenol (0.5mM) and potassium cyanide are mitochondrial inhibitors 
that activate AMPK by a mechanism involving an increase in AMP:ATP ratio and 
phosphorylation of AMPK- at T172 ([103], [104]). 
 Oxidative stress (0.6-1mM H2O2) activates AMPK by a mechanism involving 
an increase in AMP:ATP ratio. Activation correlates with phosphorylation of AMPK- 
at Thr172 ([58], [105]). 
 Inhibitors of the MAP kinase (ERK) cascade PD98059 and U0126 activate 
AMPK by increasing the AMP:ATP ratio [106]. 
 Thiazolidinediones (TZDs) are activators of the peroxisome proliferator-
activated receptor  (PPAR in adipose tissue. TZDs are inhibitors of respiratory 
chain complex I; TZDs reduced cell respiration and increased anaerobic respiration 
[107]. Rosiglitazone, (200M), a thiazolidinedione used in the treatment of type 2 
diabetes, activates AMPK (both 1 and 2) in muscle by a mechanism involving an 
increase in the AMP:ATP ratio and phosphorylation of AMPK- at Thr172 [103]. 
Pioglitazone and troglitazone have the same effect ([108], [109]). 
 Leptin, a hormone secreted by adipocytes, regulates food intake, energy 
expenditure and has neuroendocrine function. It stimulates fatty acid oxidation and 
glucose uptake in liver, pancreas and skeletal muscle and prevents the accumulation of 
lipids in non-adipose tissues. Leptin stimulates AMPK activity in skeletal muscle. 
Activation of AMPK correlates with an increase in the phosphorylation of Thr172 of 
AMPK-2. Leptin activates AMPK in a biphasic fashion, through AMP:ATP dependent 
and independent mechanisms [110]. Mice deficient in leptin or leptin-receptors contain 
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lower AMPK activity in muscle and/or liver [111]. However, leptin inhibits AMPK in 
the hypothalamus [112]. 
 Adiponectin (ACRP30), another hormone secreted by adipocytes, regulates 
energy homeostasis and glucose and lipid metabolism (stimulates -oxidation and 
glucose uptake). It increases the AMP:ATP ratio, leading to phosphorylation at Thr172 
an activation of AMPK [113]. Adiponectin also inhibits hypertrophic signaling in the 
myocardium through activation of AMPK signaling ([112], [114]). 
 -Lipoic acid. Similar to leptin, -lipoic acid has two separate functions. On 
one hand, it is able to activate AMPK in skeletal muscle, improving fatty acid oxidation 
and insulin-stimulated glucose uptake [115]. On the other hand, -lipoic acid is able to 
inhibit AMPK activity at the neuronal level ([112], [116]). 
 
7.2.2.- AMPK activating compounds independent of AMP/ATP ratio. 
 Peroxynitrite (ONOO-) increases AMPK activity (increase in Thr172 
phosphorylation) without changing cellular AMP. AMPK activation involves the c-
Src/PI3-kinase pathway ([117], [118]). 
 Metformin, (2 mM), a drug currently used in treatment of type 2 diabetes [119], 
activates AMPK in vivo. Activation occurs after 30 to 60 min and causes a Thr172 
phosphorylation in both AMPK-1 and 2. Activation of AMPK by metformin is 
mediated by mitochondrial reactive nitrogen species (RNS); depletion of mitochondria 
or overexpression of superoxide dismutases, as well as inhibition of endothelial nitric-
oxide synthase, abolished metformin-enhanced phosphorylation of AMPK. In eNOS 
knock-out mice, metformin is unable to activate AMPK. These data suggest that RNS 
generated in mitochondria by metformin is required for AMPK activation in vivo. This 
activation requires the c-Scr/PI3Kinase pathway [120]. Phenformin (2 mM) has a 
similar effect as metformin, but actives AMPK more rapidly [74]. As mentioned above, 
LKB1 is also required for the activation of AMPK by metformin [88] and phenformin 
[87] in different tissues. 
 Osmotic stress (0.4-0.6M sorbitol) also activates AMPK (with Thr172 
phosphorylation) without changing the AMP:ATP ratio; it acts via CaMKK to activate 
AMPK ([58], [103], [121]). 
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 Estradiol. AMPK activation by estradiol was independent of both AMP levels 
and ER (estrogen receptor ), but required estradiol conversion to its catechol 
metabolites [122]. 
 Low levels of glucose. Similarly to the yeast SNF1 complex, low glucose 
improves AMPK activity. The activation correlates with an increase in the 
phosphorylation of Thr172 and does not depend on the levels of AMP or ATP [123]. 
 Long-chain saturated and monounsaturated fatty acids (palmitate C16, 
stearate C18, oleate C18:1) (0.5mM) activate AMPK in heart inducing 
phosphorylation of Thr172 by a mechanism not dependent on the AMP:ATP ratio. 
Activation of AMPK by palmitate [124] was prevented by treating the samples with 
PP2C phosphatase, leading to the conclusion that exposure to fatty acid caused either an 
activation of an AMPK upstream kinase or an inhibition of an AMPK phosphatase 
[125]. 
 The release of nucleotides (ATP, ADP and UTP, but not UDP) from damaged 
tissues induces phosphorylation and activation of AMPK in HUVEC cells, by a 
mechanism not linked to changes in AMP:ATP ratio. AMPK activation is mediated by 
P2Y1, P2Y2 and P2Y4 nucleotide receptors. Adenosine also induces phosphorylation of 
AMPK that was not mediated by P1 receptors, but required adenosine uptake [126]. 
Adenosine uptake is mediated by CNT2 transporters; therefore, nucleoside transporters 
might be novel players in the complex regulation of AMPK and energy metabolism 
[127]. 
 AMPK is also activated by agonists of different membrane receptors. 
Stimulation of Gq-coupled receptors (GCRP) specifically activates AMPK-1. In this 
sense, platelet-activation factor, norepinephrine and bradykinin activate AMPK when 
they bind to their respective Gp-coupled receptors [128]. Activation of AMPK in 
skeletal muscle is dependent on 1-adrenoceptors and not on 2- or -adrenoceptors, 
being the AMP:ATP ratio unaltered after 1-adrenergic stimulation [129]. On the other 
hand, in 3T3-L1 adipocytes, activators of adenylate cyclase (forskolinor -adrenergic 
agonist isoproterenol) or analogues of cAMP promoted phosphorylation and activation 
of AMPK, which was prevented by insulin [130]. Activation of AMPK in brown 
adipocytes is mediated by - but not -adrenoceptors and is independent of UCP1 
[131]. 
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 Recently, a new activator of AMPK, namely A769622, has been described 
[132]. A769622 activates AMPK both allosterically and by inhibiting 
dephosphorylation of AMPK on Thr-172. Its mechanism of action does not involve 
binding to the  subunit, as AMP does. However, its allosteric effect is abolished in an 
AMPK complex lacking the glycogen binding domain of the  subunit, and a mutation 
of Ser108 to alanine in this  subunit almost completely abolishes activation of AMPK 
by A769662 ([133], [134]).  
 
 In addition, it has been recently described that natural plant products with 
beneficial metabolic effects in diabetic and insulin-resistant states, such us berberine 
[135], resveratrol (present in grapes and red wine) [136], epigallocatechin-3-gallate 
(present in green tea) [137], theaflavins (present in black tea) [138], caffeic acid 
phenethyl ester (present in honeybee propolis) [139], cucurbitane triterpenoids 
(present in bitter melon) [140], activate AMPK. However, in most cases the mechanism 
of activation is unclear. 
 
7.3.- AMPK inactivation. 
In yeast, the activity of the three upstream kinases (Sak1, Elm1 and Tos3) seems 
to be constitutive, so the regulation of the phosphorylation status of Snf1 depends on the 
phosphatase involved in the dephosphorylation of Thr210. In this sense, some reports 
indicate that the yeast PP1 protein phosphatase, Glc7, and its regulatory subunit, Reg1, 
are responsible for the dephosphorylation and inactivation of the Snf1 protein kinase, in 
response to glucose ([141], [142]). In the absence of Reg1, Glc7 can not perform its 
function, so the Snf1 kinase complex is constitutively in the active, phosphorylated 
state, even in the presence of glucose ([141], [142]) (Fig. 5A). 
As described above, activation of the AMPK complex requires phosphorylation 
of AMPK- subunit at Thr172 by an upstream kinase. Studies on how these upstream 
kinases are regulated indicate that they are constitutively expressed and that increases in 
AMP do not stimulate their activity; only a rise in Ca++ activates CaMKK’s ([75], [85]), 
thus leaving open the question of how phosphorylation of AMPK- is regulated. 
Perhaps, and as in the case of the yeast Snf1 complex, the regulation depends on the 
activity of the phosphatase involved in the dephosphorylation of Thr172 (Fig. 5B). 
Despite several attempts made to characterize this phosphatase, its identity is still 
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unknown. In vitro studies have identified PP1, PP2A and PP2C protein phosphatases as 
possible candidates ([48], [143]). In addition, it has also been described that PP2A is 
involved in the regulation of the interaction of AMPK- and AMPK- by glucose [12]. 
Also, treatment of primary hepatocytes with different protein phosphatase inhibitors 
(okadaic acid (OA) 100 nM, microcystine 300 nM, calyculin A 100 nM, cantharidin 30 
M, tautomycin 1 M) produces the same high molecular weight AMPK- forms 
compatible with phosphorylated proteins, also present in AICAR treated cells. The 
appearance of these forms correlates with higher AMPK activity measured as 
phosphorylated ACC (Ser79). The presence of Naringin (100-300 M), a flavonoid 
antagonist of OA action, prevents the phosphorylation of AMPK induced by OA, 
microcystin and AICAR, but not that produced by calyculin A or cantharidine, 
suggesting that AMPK- may be activated by two independent mechanisms, one being 
naringin-sensitive (PP2A-associated) and the other being naringin-resistant (PP1-
associated). Toxins (and AICAR) do not stimulate AMPK phosphorylation by LKB1 
activation, but rather by increasing the susceptibility of AMPK to be phosphorylated by 
LKB1. Naringin could act on AMPK itself (acting as an AMP antagonist) or on a 
protein kinase involved in permissive AMPK phosphorylation [144]. Additionally, it 
has been recently reported that activation of protein phosphatase 2A by palmitate 
inhibits AMPK, suggesting a negative role of PP2A in the regulation of AMPK activity 
in vivo [145]. 
Recently it has been suggested that AMP, in addition to allosterically stimulating 
AMPK activity, could inhibit all phosphatases acting on AMPK, since it can prevent the 
in vitro dephosphorylation of Thr172-P in AMPK-by PP2C This effect requires a 
functional AMPK- subunit, since AMP can not prevent the dephosphorylation of 
Thr172 in  complexes containing forms of the  subunit that bind AMP poorly. 
According to this model, increased Thr172 phosphorylation by LKB1 would occur in 
response to decreased dephosphorylation following a rise in AMP. Dephosphorylation 
and inactivation of AMPK would occur when the concentration of AMP returned to 
basal levels [62]. 
 
7.4.- Methods for inhibiting AMPK activity. 
 There are several methods for inhibiting AMPK activity (TableIII): 
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AMPK-1 K45R, D157A and T172A mutant forms may be used as dominant 
negative alleles of AMPK since they compete with endogenous AMPK- for the 
binding of  and -subunits ([40], [45], [146]). 
Creatine phosphate and ATP inhibit AMPK. This effect is entirely allosteric; 
they do not affect AMPKK ([60], [64]). 
Compound C is a reversible inhibitor of AMPK [89], although it inhibits 
additional protein kinases and has AMPK-independent effects [147]. Caution has to be 
taken when using this compound because it inhibits the uptake of AICAR, so when 
combined with AICAR, no activation of AMPK is observed because no AICAR is taken 
by the cells. The same is true for some p38-MAPK inhibitors like SB202190 and 
SB203580 [148]. 
C75 (40 g/ml) (a synthetic inhibitor of fatty acid synthase and an activator of 
carnitine palmitoyltransferase-1) increases fatty acid oxidation and ATP production 
leading to the inhibition of AMPK. The C75-mediated inactivation of AMPK at the 
hypothalamus may explain the food-intake reducing effects of C75 ([149], [150]). 
Leptin and -lipoic acid both are able to decrease hypothalamic AMPK 
activity, causing profound weight loss in rodents by reducing food intake and enhancing 
energy expenditure ([112], [115], [116]). 
High levels of glycogen decrease AMPK activity [151]. High levels of glucose 
also decrease AMPK activity in both -cells [152] and skeletal muscle [123]. 
Ethanol also inhibits liver AMPK. This inhibition accounts for the observed 
activation of hepatic ACC and development of alcoholic fatty acid liver [153]. 
Insulin antagonizes the activation of AMPK. The effect of insulin (that was 
blocked by wortmannin, an inhibitor of phosphatidylinositol-3-kinase) occurred only if 
insulin was added before AMPK activation, and resulted in a decreased phosphorylation 
of AMPK Thr172, being unrelated to changes in the AMP:ATP ratio [154]. In cardiac 
cells, inhibition by insulin is dependent on Akt; insulin caused an increased Akt 
phosphorylation (mediated by PI3-kinase) and a decrease in AMPK phosphorylation at 
Thr172; in fact, a constitutively active form of Akt displayed decreased phosphorylation 
of AMPK [155]. It has been recently reported that Akt is able to phosphorylate AMPK-
 subunit at Ser4851/4912 site. This phosphorylation prevents LKB1 
phosphorylation at SerT172, decreasing the activity of AMPK ([49], [50]). 
 26
cAMP-PKA can also phosphorylate AMPK- at Ser4851/4912 site, 
decreasing then the phosphorylation at Thr172 and AMPK activity. cAMP agonists 
such as forskolin, isobutylmethylxanthine and glucose-dependent insulinotropic peptide 
(GIP) inhibit AMPK by this mechanism [51]. Is has also been proposed that the 
Ser4851/4912 site could be a site for autophosphorylation, playing a role in limiting 
AMPK activation in response to energy depletion or other regulators [51]. 
Resistin, another adipokine, seems to have opposite effects to adiponectin. It 
inhibits AMPK. Knock-out mice lacking resistin have low blood glucose due to reduced 
glucose production by the liver, and this is associated with activation of AMPK and 
reduced expression of enzymes of gluconeogenesis ([112], [156]). 
Staurosporine (2.9 nM) [157], Iodotubercidin (10 M) [158] and 9--D-
arabinofuranoside (ara-A) (2.5 mM) [158] have been used as inhibitors of AMPK. 
However they are not specific since they can inhibit additional protein kinases. 
 
8.- PERSPECTIVES 
 Although a lot of efforts have been made to understand the structure and 
regulation of the activity of AMPK complex, there are still some areas of missing 
information. For example, only partial crystal structures of the complex are available 
and they all lack the kinase catalytic domain and the autoinhibitory region. It would be 
very interesting to see how the kinase catalytic subunit folds around the other 
components of the heterotrimeric complex and validate the biophysical results already 
obtained. These results will allow us to understand to relationship between the kinase 
catalytic domain and the autoinhibitory region and how the CBS domains of  subunit 
play a role in the activation of the kinase subunit. This information will be very 
important for the design of specific drugs that could either activate or inactivate specific 
AMPK complexes in targeted tissues. 
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Table I: Characteristics of different structures of AMPK heterotrimeric complexes. 
 
 
 
 
Townley et al 
[52] 
 
 
Xiao et al 
[53] 
 
 
Amodeo et al 
[54] 
 
Organism 
 
Schizosaccharomyces 
pombe 
 
Rattus novergicus 
 
Saccharomyces 
cerevisiae 
 
 
PDB number 
 
2OOX 
 
2V8Q 
 
2QLV 
 
 
Components 
(residues in 
brackets) 
 
440-576) 
205-298) 
1-334; full length) 
 
1(396-548) 
2 (187-272) 
1(1-331; full length) 
 
Snf1(398-633) 
Sip2(154-415) 
Snf4 (1-322; full length) 
 
 
Overall structure 
 
Dimer of 
heterotrimers 
 
Monomer of 
heterotrimer 
 
 
Dimer of heterotrimers 
 
Structure of 
monomer 
 
Triangular 
 
Triangular.  and  
subunits twisted 12º 
respect to S. pombe 
structure 
 
Triangular.  and  
subunits twisted 12º 
respect to S. pombe 
structure 
 
 
Number of AMP 
bound 
 
1 (AMP3 site) 
 
3 (AMP1, AMP2 and 
AMP3 sites) 
 
 
1 (AMP3 site) 
 
Additional features 
 
 
 
 
 
Snf1 regulatory domain 
bound to CBS4 region of 
Snf4; Sip2 GBD bound 
to CBS2 region of Snf4 
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Table II: Methods for activating AMPK 
 
 
AMPK activation 
affecting 
AMP/ATP ratio 
 
 
 
 
Reference 
 
AMPK activation 
without altering 
AMP/ATP ratio 
 
 
 
Reference 
 
AICAR 
 
[94] 
 
Peroxynitrite 
 
[117] 
 
Dinitrophenol 
 
[103] 
 
Metformin 
 
[120] 
 
H2O2 
 
[105] 
 
Osmotic stress 
 
[58] 
 
Inhibitors of MAP 
kinase cascade 
 
 
[106] 
 
Estradiol 
 
[122] 
 
Thiazolidinediones 
 
[103] 
 
Low glucose 
 
[123] 
 
Leptin (in muscle) 
 
[110] 
 
Long chain saturated 
and monosaturated 
fatty acids 
 
[124] 
 
Adiponectin 
 
[113] 
 
Agonists of 
nucleotide receptors 
 
[126] 
 
-Lipoic acid  
(in muscle) 
 
[115] 
 
Agonists of 1-
adrenoreceptors 
 
[129] 
 
 
 
 
 
A769662 
 
[132] 
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Table III: Methods for inactivating AMPK 
 
 
AMPK inactivation 
 
 
Reference 
 
Dominant negative forms of AMPK- 
 
[40], [45] 
 
Creatine phosphate and ATP 
 
[60], [64] 
 
Compound C 
 
[89], [148] 
 
C75 (hypothalamus) 
 
[149], [150] 
 
Leptin (hypothalamus) 
 
[112] 
 
-Lipoic acid (hypothalamus) 
 
[116], [115] 
 
Glycogen 
 
[151] 
 
High glucose 
 
[152], [123] 
 
Ethanol 
 
[153] 
 
Staurosporine 
 
[157] 
 
Iodotubercidin 
 
[158] 
 
9-b-D-arabinofuranoside 
 
[158] 
 
Insulin (heart) 
 
[154], [155] 
 
Agonists of cAMP-PKA pathway 
 
[51] 
 
Resistin 
 
[156] 
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FIGURE LEGENDS 
Fig. 1: Diagram of mammalian AMPK and yeast SNF1 subunits. KD, kinase domain; 
RD, regulatory domain; AID, auto-inhibitory domain; GBD, glycogen bind domain; 
ASC, association with Snf1 complex domain; Myr, myristoylation; CBS, cystathionine-
-synthase domain. 
 
Fig. 2: Crystal structure models of different kinase domains of  subunits. The crystal 
structure of the kinase domains of Snf1 (PDB, 2EUE), (PDB, 2FH9) and AMPK-2 
(PDB, 2H6D) were modeled using the PyMol programme (DeLano Scientific). The 
small N-terminal and the large C-terminal domains are indicated. In the case of the 
2FH9 model, the second protomer in colored in yellow. The position of K45 and D157 
residues in AMPK-2 subunit is also indicated. 
 
Fig. 3: A) The crystal structure model of GBD domain of AMPK- subunit (PDB, 
1Z0M) was modeled using the PyMol programme (DeLano Scientific). Residues 
involved in carbohydrate binding (K126, W133, L146 and N150) and the -
cyclodextrin ring (yellow) are indicated. B) Crystal structure model of a CBS domain 
pair from human AMPK-1 (residues 182-325, comprising CBS3 plus CBS4) in 
complex with AMP (PDB, 2UV4). The conserved  structures of CBS3 (yellow) 
and CBS4 (purple), the sheet of the three -strands in each CBS domain and the AMP 
molecule is indicated. 
 
Fig. 4: A) Crystal structure model of the heterotrimeric core of Saccharomyces 
cerevisiae SNF1 complex (PDB, 2QLV) was modeled using the PyMol programme 
(DeLano Scientific).  subunit (Snf1) is colored in purple,  subunit (Sip2) is colored in 
green and  subunit (Snf4) is colored in blue (CBS1+2) and yellow (CBS3+4). The 
position of the three-stranded -sheets from  and  subunits, the GBD domain of  
subunit, the RD domain of the  subunit and the corresponding CBS domains is 
indicated. B) Crystal structure model of the mammalian AMPK-1 subunit (PDB, 
2V8Q) in complex with AMP was modeled using the PyMol programme (DeLano 
Scientific). The conserved  structures of CBS1 (green), CBS2 (yellow), CBS3 
(purple) and CBS4 (salmon) were colored on the blue backbone. The position of three 
AMP molecules is indicated. 
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Fig. 5: Activity of the SNF1 and AMPK complexes is regulated by phosphorylation and 
-subunit dependent rearrangement. A) Snf1 complex; B) AMPK complex. See text for 
details. 
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